Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 10/2021

04.08.2021 | COVID-19 | Leukemia (A Aguayo, Section Editor) Zur Zeit gratis

The Care of the Leukemic Patients in Times of SARS-CoV-2

verfasst von: Nabin Raj Karki, Thuy Le, Jorge Cortes

Erschienen in: Current Oncology Reports | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The spread of the novel coronavirus SARS-CoV-2 and its associated disease, coronavirus disease of 2019 (COVID-19), has significantly derailed cancer care. Patients with leukemia are more likely to have severe infection and increased rates of mortality. There is paucity of information on how to modify care of leukemia patients in view of the COVID-19 risks and imposed restrictions. We review the available literature on the impact of COVID-19 on different types of leukemia patients and suggest general as well as disease-specific recommendations on care based on available evidence.

Recent Findings

The COVID-19 infection impacts leukemia subtypes in variable ways and the standard treatments for leukemia have similarly, varying effects on the course of COVID-19 infection. Useful treatment strategies include deferring treatment when possible, use of less intensive regimens, outpatient targeted oral agents requiring minimal monitoring, and prioritization of curative or life-prolonging strategies. Reducing health care encounters, rational transfusion standards, just resource allocation, and pre-emptive advance care planning will serve the interests of leukemia patients.

Summary

Ad hoc modifications based on expert opinions and extrapolations of previous well-designed studies are the way forward to navigate the crisis. This should be supplanted with more rigorous prospective evidence.
Literatur
1.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill Bull Eur sur les Mal Transm Eur Commun Dis Bull. 2020;25(10).
2.
Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMedCrossRef
3.
4.
5.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.PubMedPubMedCentralCrossRef
6.
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–45.PubMedCrossRef
7.
Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan. China. JAMA Oncol. 2020;6(7):1108–10.PubMedCrossRef
8.
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21.PubMedPubMedCentralCrossRef
9.
10.••
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020.;7(10):e737–45. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​32798473This is one of the first studies with a sizable patient population (536 COVID-19-positive patients with hematological malignancies who were hospitalized across multiple care centers in Itality). It showed that these patients had significantly worse outcomes than both healthy patients and COVID-19-negative patients with hematological malignancies. Therefore, it is vital to formulate appropriate management for these at-risk patients.
11.••
Segelov E, Underhill C, Prenen H, Karapetis C, Jackson C, Nott L, et al. Practical considerations for treating patients with cancer in the COVID-19 pandemic. JCO Oncol Pract. 2020;16(8):467–82 This article not only highlights that comprehensive care for cancer patients during the pandemic should not be interrupted or compromised but also provides reasonable changes to standard practice to be adopted by oncology clinicians.PubMedCrossRef
12.•
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, et al. Treating leukemia in the time of COVID-19. Acta Haematol. 2020:1–13 This paper outlines the expert opinion from MD Anderson (large leukemia center in USA) regarding the management of leukemia patients with and without evidence of COVID-19 published in the midst of the pandemic.
13.•
Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F, et al. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2020:1–4 This article was one of the early articles providing general approaches to acute leukemia and stem cell transplantation in the time of COVID 19 pandemic.
14.
Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, et al. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic. HemaSphere. 2020;4(4):e432.PubMedPubMedCentralCrossRef
15.
16.••
Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, et al. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020;7(8):e601–12 This article outlines the general framework for the care of patients with acute leukemia and myeloid neoplasms during COVID-19 pandemic from international experts. It addresses some key challenges related to resource allocation, scarce resouces, and access to clinical trials.PubMedPubMedCentralCrossRef
17.
18.
19.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020;383:1813–26.CrossRefPubMed
20.•
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020; This is a fairly well-designed randomized double-blind study with about 500 patients in each arm to evaluate the effectiveness of baricitinib in combination with remdesivir for adults with COVID-19. This study found that this combination was superior to remdesivir alone in decreasing recovery time and promoting clinical improvement in COVID-19 infected patients. Baricitinib is a drug used to treat rheumatoid arthritis and its role in COVID-19 was actually theorized using artificial intelligence so this also represented an exciting new way to discover new treatment alternatives.
21.
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–37.PubMedCrossRef
22.
Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44.PubMedPubMedCentralCrossRef
23.
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–51.PubMedCrossRef
24.
25.
Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol. 2020;190:e154–6.
26.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–84.PubMedPubMedCentralCrossRef
27.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020;2:e474–84.
28.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–15.PubMedCrossRef
29.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.PubMedCrossRef
30.
Gavillet M, Carr Klappert J, Spertini O, Blum S. Acute leukemia in the time of COVID-19. Leukemia research. 2020;92:106353.
31.
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32–40.PubMedCrossRef
32.
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1):28–36.PubMedPubMedCentralCrossRef
33.
Röllig C, Kramer M, Schliemann C, Mikesch J-H, Steffen B, Krämer A, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823–30.PubMedCrossRef
34.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395:1033–4.
35.
Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296(2):E115–7.PubMedCrossRef
36.
Holborow A, Asad H, Porter L, Tidswell P, Johnston C, Blyth I, et al. The clinical sensitivity of a single SARS-CoV-2 upper respiratory tract RT-PCR test for diagnosing COVID-19 using convalescent antibody as a comparator. Clin Med. 2020.
37.
Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65.PubMedCrossRef
38.
Tanasijevic AM, Revette A, Klepin HD, Zeidan A, Townsley D, DiNardo CD, et al. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020:1–5.
39.
Karlin L, Darmon M, Thiéry G, Ciroldi M, de Miranda S, Lefebvre A, et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant. 2005;36(3):245–50.PubMedPubMedCentralCrossRef
40.
Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38(3):275–83.PubMedCrossRef
41.•
Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020:1, 6 This manuscript highlights the different strategies and recommendations for stem cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy with active COVID-19 infection or known exposure. It is suggested that delaying or deferring allo-SCT may be pursued in select patients. Other strategies included back-up donors, matched related donors or haplo-identical allo-SCT.
42.•
Núñez-Torrón C, García-Gutiérrez V, Tenorio-Núñez MC, Moreno-Jiménez G, López-Jiménez FJ, Herrera-Puente P. Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19. Bone Marrow Transplant. 2020. https://​doi.​org/​10.​1038/​s41409-020-0961-yOne of the first studies to specifically compare COVID-19-positive against negative patients with AML undergoing intensive chemotherapy. While no one died in the COVID-19-negative group, three out of the four COVID-19-positive patients died due to worsening respiratory syndrome despite receiving high-dose corticosteroids. This provides vital insight into the impact of COVID-19 infection in these high risk patients.
43.
44.
Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3360–8.CrossRef
45.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood. 2019;134(Supplement_2):LBA-3. https://​doi.​org/​10.​1182/​blood-2019-132405.CrossRef
46.
47.
48.
Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801.PubMedCrossRef
49.
Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124(20):4044–55.PubMedCrossRef
50.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic. Cancer. 2019;125(15):2579–86.PubMed
51.
52.
53.
54.
55.
Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93(1):91–9.PubMedCrossRef
56.
57.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–31.PubMedPubMedCentralCrossRef
58.
59.
60.
Wolff F, Leisch M, Greil R, Risch A, Pleyer L. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal. 2017;15(1):13.PubMedPubMedCentralCrossRef
61.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102.PubMedPubMedCentralCrossRef
62.
Niyongere S, Lucas N, Zhou J-M, Sansil S, Pomicter AD, Balasis ME, et al. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019;33(1):205–16.PubMedCrossRef
63.
64.
65.
66.
67.
68.
69.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137–146.e3.PubMedPubMedCentralCrossRef
70.
71.
Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–91.PubMedPubMedCentralCrossRef
72.
73.••
GICG E, EGW H, NMA B, Westerweel PE. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study. Leukemia. 2020;34:2533–5 This study was a prospective Dutch observational study assessing the differences in susceptibility for COVID-19 and the severity of the disease course in adult CML patients and their adult housemates (included as control group). They found no significantly increased prevalance of COVID-19 in CML patients. This study also suggested that patients can safely continue their TKI.
74.•
Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34(7):1799–804. https://​doi.​org/​10.​1038/​s41375-020-0853-6First article to report on COVID-19 in pateints with CML. They found an increased prevalance of COVID-19 infection in CML patients in Hubei, China, when compared to the prevalance of the general population in that particular region. The major drawback of this retrospective observational analysis was that follow-up data were not provided and the control group was not included.CrossRefPubMedPubMedCentral
75.
Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2020;1078155220953198.
76.
77.
78.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354–63.PubMedCrossRef
79.
Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48).
80.
Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol. 2020;190:e73–6.
81.
Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912–5.PubMedCrossRef
82.
Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Vol. 50, Seminars in arthritis and rheumatism. United States. 2020:1087–8.
83.
84.
Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. England: Annals of the rheumatic diseases; 2020.
85.
Mohtadi N, Ghaysouri A, Shirazi S, Ansari S, Shafiee E, Bastani E, et al. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology. 2020;548:1–5.PubMedCrossRef
86.
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open forum Infect Dis. 2020;7(3):ofaa102.PubMedPubMedCentralCrossRef
87.
Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018;103:e307–10.
88.
89.
Dowell SF, Ho MS. Seasonality of infectious diseases and severe acute respiratory syndrome-what we don’t know can hurt us. Lancet Infect Dis. 2004;4(11):704–8.PubMedPubMedCentralCrossRef
Metadaten
Titel
The Care of the Leukemic Patients in Times of SARS-CoV-2
verfasst von
Nabin Raj Karki
Thuy Le
Jorge Cortes
Publikationsdatum
04.08.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Current Oncology Reports / Ausgabe 10/2021
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01111-0

Weitere Artikel der Ausgabe 10/2021

Current Oncology Reports 10/2021 Zur Ausgabe

Melanoma (RJ Sullivan, Section Editor)

Next-Generation Immunotherapy Approaches in Melanoma

Geriatric Oncology (L Balducci, Section Editor)

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly

Anesthesiology and Critical Care (JP Cata, Section Editor)

Targeting the mu-Opioid Receptor for Cancer Treatment

Leukemia (A Aguayo, Section Editor)

3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

Cardio-oncology (EH Yang, Section Editor)

Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation

Integrative Care (C Lammersfeld, Section Editor)

A Systematic Review and Quality Assessment of Breast Cancer Clinical Practice Guidelines Providing Complementary and Alternative Medicine Recommendations

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise